Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.
作者信息
Charest Alain
机构信息
Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Neuro Oncol. 2022 Mar 12;24(3):396-397. doi: 10.1093/neuonc/noab278.
Abstract
摘要
相似文献
1
Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.
Neuro Oncol. 2022 Mar 12;24(3):396-397. doi: 10.1093/neuonc/noab278.
2
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162.
3
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
4
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Clin Oncol (R Coll Radiol). 2008 Feb;20(1):97-8. doi: 10.1016/j.clon.2007.09.011. Epub 2007 Oct 24.
5
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Neurosurg Clin N Am. 2012 Apr;23(2):307-22, ix. doi: 10.1016/j.nec.2012.01.007.
6
Chemotherapy for glioblastoma multiforme (GBM).
Surg Neurol. 2006 Feb;65(2):107-8. doi: 10.1016/j.surneu.2005.11.054.
7
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Neurology. 2013 Jul 2;81(1):93-4. doi: 10.1212/WNL.0b013e318297eea6. Epub 2013 May 17.
8
Sex as a biological variable in response to temozolomide.
Neuro Oncol. 2017 Jun 1;19(6):873-874. doi: 10.1093/neuonc/nox040.
9
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
J Hematol Oncol. 2018 Feb 27;11(1):32. doi: 10.1186/s13045-018-0576-6.
10
Radiation as a foundation for glioblastoma therapy in elderly patients. In Regard to Arvold et al.
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):217-8. doi: 10.1016/j.ijrobp.2015.05.006.
引用本文的文献
1
Updates in IDH-Wildtype Glioblastoma.
Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.
本文引用的文献
1
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162.
2
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Br J Cancer. 2020 Oct;123(9):1360-1369. doi: 10.1038/s41416-020-1010-8. Epub 2020 Aug 3.
3
Microtubule-targeting agents and their impact on cancer treatment.
Eur J Cell Biol. 2020 May;99(4):151075. doi: 10.1016/j.ejcb.2020.151075. Epub 2020 May 1.
4
EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.
Oncotarget. 2020 Feb 25;11(8):759-774. doi: 10.18632/oncotarget.27374.
5
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Clin Cancer Res. 2020 Mar 1;26(5):1094-1104. doi: 10.1158/1078-0432.CCR-19-0909. Epub 2019 Dec 18.
6
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Invest New Drugs. 2020 Aug;38(4):1067-1076. doi: 10.1007/s10637-019-00850-z. Epub 2019 Aug 30.
7
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Radiother Oncol. 2017 Sep;124(3):433-438. doi: 10.1016/j.radonc.2017.07.024. Epub 2017 Aug 7.
8
The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.
Mol Cancer Ther. 2016 Nov;15(11):2740-2749. doi: 10.1158/1535-7163.MCT-16-0252. Epub 2016 Aug 18.
9
A co-clinical platform to accelerate cancer treatment optimization.
Trends Mol Med. 2015 Jan;21(1):1-5. doi: 10.1016/j.molmed.2014.10.008. Epub 2014 Nov 17.
10
The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
J Mol Biol. 2014 Apr 17;426(8):1848-60. doi: 10.1016/j.jmb.2014.02.005. Epub 2014 Feb 11.
Zotero 插件